Compare Merck & Co., Inc. (MRK) vs Occidental Petroleum Corporation (OXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Occidental Petroleum Corporation — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while Occidental Petroleum Corporation trades at $61.06 (market cap $60.63B). The key difference: Merck & Co., Inc. is far larger — about 6× Occidental Petroleum Corporation's market cap, and Merck & Co., Inc. pays the higher dividend (2.29%). Which is the better fit depends on your goals.
| MRK | OXY | |
|---|---|---|
Market Cap | $366.28B | $60.63B |
Sector | Health | Energy |
52-Week High | $156.43 | $66.24 |
52-Week Low | $77.60 | $38.92 |
Enterprise Value | $413.04B | $79.39B |
Dividend Yield | 2.29% | 1.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
Occidental Petroleum (OXY) trades at $60.65, up 1.02% with strong technical momentum and bullish moving average signals. The company demonstrates robust profitability with 30.32% net income margin and 21.46% ROE, while trading at reasonable valuations (P/E 17.89, EV/EBITDA 5.59). Recent earnings beats and improving balance sheet with debt reduction to $25.32 billion support positive sentiment.
OXY presents a compelling opportunity with analyst consensus target of $68.67 (13% upside) and 50% buy ratings. Key catalysts include continued debt reduction, projected 2026 net margin expansion to 30.31%, and oil price tailwinds. Risks include oil price volatility, execution on production targets, and macroeconomic headwinds affecting energy demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →
